Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 5:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 1,639 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Functional Medicine Clear all
Terminated No phase listed Observational

Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma

NCT03777410
View directory record Official record
Conditions
Multiple Myeloma in Relapse
Interventions
Not listed
Lead sponsor
Travera Inc
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
4
States / cities
Duarte, California • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 15, 2026, 5:57 PM EDT
Recruiting Not applicable Interventional

Islet Transplantation in Patients With "Brittle" Type I Diabetes

NCT01630850
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Allogenic islet cells (human, U. Chicago), Intraportal infusion of islet cells
Biological · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 15, 2026, 5:57 PM EDT
Recruiting Phase 2 Interventional

Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections

NCT05639647
View directory record Official record
Conditions
Gram-negative Bacterial Infections
Interventions
ATM-AVI, BAT
Drug
Lead sponsor
Pfizer
Industry
Eligibility
9 Months to 17 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
San Diego, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 15, 2026, 5:57 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Changes in Endothelial Function and Biomarkers in African Americans (AA) With Metabolic Syndrome

NCT01271374
View directory record Official record
Conditions
Hypertension
Interventions
amlodipine and olmesartan, losartan and HCTZ
Drug
Lead sponsor
InVasc Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Tucker, Georgia
Source: ClinicalTrials.gov public record
Updated May 5, 2011 · Synced Oct 15, 2026, 5:57 PM EDT
Completed Not applicable Interventional Results available

Adapting Behavioral Activation to Technology Platform

NCT03783533
View directory record Official record
Conditions
Depression
Interventions
Behavioral Activation
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
13 Years to 17 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 16, 2022 · Synced Oct 15, 2026, 5:57 PM EDT
Not listed Not applicable Interventional

Cryoablation of Intercostal Nerves for Post-Operative Pain Management in Opioid-Tolerant Patients

NCT05276258
View directory record Official record
Conditions
Pain, Pain, Postoperative
Interventions
cryoSPHERE Ablation, Bupivacaine
Device · Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 90 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Oct 15, 2026, 5:57 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cardiovascular, Cerebrovascular, and Cognitive Function in Spinal Cord Injury

NCT02122991
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Not listed
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
30 Years to 64 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Oct 15, 2026, 5:57 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Blood Brain Flow and Exercise

NCT02653638
View directory record Official record
Conditions
Cerebrovascular Circulation
Interventions
Control, Indomethacin
Other · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Oct 15, 2026, 5:57 PM EDT
Terminated Phase 2 Interventional

To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia

NCT04311515
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Tau Positron emission tomography (PET), Fluorodeoxyglucose (FDG) Positron emission tomography (PET), Cerebrospinal fluid (CSF) Biomarkers, Blood Biomarkers, Rating Scales, PU-AD, Placebo
Radiation · Diagnostic Test · Behavioral + 1 more
Lead sponsor
Samus Therapeutics, Inc.
Industry
Eligibility
55 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
10
States / cities
Boca Raton, Florida • Delray Beach, Florida • Lake Worth, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Oct 15, 2026, 5:57 PM EDT
Active, not recruiting Phase 2 Interventional

Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule

NCT06812988
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Brivekimig, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years to 35 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Atlanta, Georgia • Columbus, Georgia • Farmington Hills, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 15, 2026, 5:57 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Botulinum Toxin A Injection in Patients With Painful Artificial Knee Arthroplasty (TKA)

NCT00403273
View directory record Official record
Conditions
Knee Pain
Interventions
Botulinum toxin A, Normal Saline
Drug
Lead sponsor
Minneapolis Veterans Affairs Medical Center
Federal
Eligibility
Not listed
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Oct 15, 2026, 5:57 PM EDT
Completed Phase 1 Interventional

Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.

NCT03666273
View directory record Official record
Conditions
Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
Interventions
Bapotulimab (BAY1905254), Bapotulimab (BAY1905254) + Pembrolizumab (KEYTRUDA®)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
8
States / cities
Tucson, Arizona • New Haven, Connecticut • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Oct 15, 2026, 5:57 PM EDT
Completed Early Phase 1 Interventional

Effects of 4-AP on Functional SCI Recovery

NCT05447676
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Dalfampridine, Placebo drug, STDP stimulation, Exercise training
Drug · Other · Behavioral
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 85 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 15, 2026, 5:57 PM EDT
Completed Phase 2 Interventional Results available

Reduced Carbohydrate Versus Fat in Obese Subjects

NCT00846040
View directory record Official record
Conditions
Obesity
Interventions
Reduced fat diet, Reduced carbohydrate diet, Drug: f-18 fallypride, fMRI, PET
Other · Drug · Device
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 45 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 15, 2021 · Synced Oct 15, 2026, 5:57 PM EDT
Completed Phase 1 Interventional

A Study to Learn How the Body Processes the Study Medicine Called Osivelotor (PF-07940367) in People With Loss of Liver Function

NCT06340347
View directory record Official record
Conditions
Liver Diseases
Interventions
Osivelotor
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
3
States / cities
Lake Forest, California • Tampa, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 10, 2025 · Synced Oct 15, 2026, 5:57 PM EDT
Completed Phase 2 Interventional

Cognitive Behavioral Therapy for Post Traumatic Stress Disorder in Addiction Treatment

NCT01456338
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic, Substance-Related Disorders
Interventions
Cognitive Behavioral Therapy for PTSD, Individual Addiction Counseling
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
Hartford, Connecticut • Lebanon, New Hampshire • Manchester, New Hampshire + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2011 · Synced Oct 15, 2026, 5:57 PM EDT
Completed Not applicable Interventional Results available

Implementing Prescriber-Pharmacist Collaborative Care for Evidence-based Anticoagulant Use

NCT05351749
View directory record Official record
Conditions
Pulmonary Embolism, Venous Thromboembolism, Atrial Fibrillation
Interventions
New-prescription Alert, New-prescription Alert with referral option, Existing-prescription notification to prescriber, Existing-prescription notification to pharmacist
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
Not listed
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 15, 2026, 5:57 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Citicoline on Brain Function and Behavior in Marijuana-Dependent Individuals

NCT00158249
View directory record Official record
Conditions
Marijuana Abuse
Interventions
citicoline, placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2014 · Synced Oct 15, 2026, 5:57 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Non-invasive Measurement of Cerebrovascular Reactivity After Traumatic Brain Injury

NCT02990078
View directory record Official record
Conditions
TBI
Interventions
Sildenafil citrate, Functional Near Infared Spectroscopy, Hypercapnia Challenge
Drug · Device · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Oct 15, 2026, 5:57 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Study of Changes in Total Cholesterol Levels as a Function of Consuming a Supplement Designed to Improve Cardiovascular Health

NCT01890889
View directory record Official record
Conditions
Cholesterol, Hyperlipidemia, Hypercholesteremia
Interventions
Ad-Chol-Pre, Half-dose Ad-Chol-Pre, Defatted egg yolk without the active ingredient of the other two interventions
Dietary Supplement · Other
Lead sponsor
Integrative Health Technologies, Inc.
Network
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 15, 2026, 5:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-Dose Pharmacokinetics and Safety of Oral Lofexidine in Hepatically-Impaired Subjects

NCT02318836
View directory record Official record
Conditions
Liver Failure
Interventions
Lofexidine Hydrochloride (HCl) tablets
Drug
Lead sponsor
USWM, LLC (dba US WorldMeds)
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 15, 2026, 5:57 PM EDT
Completed Not applicable Interventional Results available

Mobile After-Care Intervention to Support Post-Hospital Transition (MACS)

NCT03769493
View directory record Official record
Conditions
Psychotic Disorders
Interventions
Mobile After-Care Support (MACS) app
Behavioral
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Oct 15, 2026, 5:57 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Magnesium L-Threonate on Sleep, Recovery, and Athletic Performance in Collegiate Athletes

NCT07015047
View directory record Official record
Conditions
Recovery of Function (G11.427.698.620), Athletic Performance, Heart Rate Variability (HRV)
Interventions
Magnesium L-Threonate, Placebo
Dietary Supplement · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 35 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 15, 2026, 5:57 PM EDT
Recruiting Not applicable Interventional

Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma

NCT05312255
View directory record Official record
Conditions
Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma
Interventions
Behavioral Intervention, Beta-Adrenergic Antagonist, Propranolol, Quality-of-Life Assessment, Questionnaire Administration, Resistance Training, Short-Term Fasting
Behavioral · Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Oct 15, 2026, 5:57 PM EDT